Ofatumumab exemplifies this approach in RA, where subcutaneous administration achieved ACR50 responses in 41.2% of TNF-α refractory patients (207) and reduced synovial ectopic lymphoid structures by 68% (208), suggesting direct targeting of pathogenic B-cell niches. Here, TNF is linked to rheumatoid arthritis.